Artificial Intelligence used to identify existing drugs that could treat AMDWednesday 17 April 2019
An artificial intelligence company and a collaboration between four UK-based sight loss charities has found that a number of existing drugs could possibly reduce sight loss from age-related macular degeneration.
Action Against AMD, formed of the Macular Society, Scottish War Blinded, Fight for Sight and Blind Veterans UK, partnered with the artificial intelligence company BeneloventAI to conduct the research.
The artificial intelligence platform ‘Benevolent Platform’ was used to review research consisting of millions of scientific papers, clinical trials, and other information related to AMD, with a view to identifying potential treatments.
This research identified seven drugs that are either in development, or already being used to treat other conditions, could potentially be repurposed to treat macular degeneration. Action Against AMD plan to take the learnings from the project to prioritise which of the potential treatments should be investigated.
The Chief Executive for Action Against AMD, Dr Wen Hwa Lee, said: “It’s really promising that we have identified current drugs that may have a positive effect on macular degeneration. Our next step will be to confirm which of these drugs have the potential to slow progression of the disease and reduce sight loss for people with this condition.”
AI could identify existing drugs to help eye disease.
Labels:Sight News, AMD
A Serious Blog
News and views from around the world on lighting, eyecare and eye conditions.
- Why mood lighting might be ruining your dinner
- 3 surprising ways the clocks going back can affect your well-being
- Aspirin linked to greater risk of macular degeneration
- Increased screen time during the pandemic could be affecting your vision
- How light affects productivity and wellbeing